Paediatric Respiratory Reviews
Volume 6, Issue 3 , Pages 227-235 , September 2005

Macrolides and airway inflammation in children

References 

  1. Washington JA, Wilson WR. Erythromycin. A microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc. 1985;60:189–203
  2. Kaplan MA, Golden M. The use of triacetyloleandomycin in chronic infectious asthma. In: Antibiotic Annual. New York Interscience Publishers, 1958–1959; pp. 273–276.
  3. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy. 1970;45:146–162
  4. Kudoh S, Uetake T, Hagiwara K, et al. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi. 1987;25:632–642
  5. Nakanishi N, Ueda N, Kitade M, Moritaka T. [A case of cystic fibrosis in a Japanese student]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995;33:771–774
  6. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978–984
  7. Rubin BK, Tamaoki J. Antibiotics as anti-inflammatory and immunomodulatory agents. Basel: Birkhäuser Verlag; 2004;
  8. Shiomi S, Omura S. Discovery of new macrolides.. In:  Omura S editors. Macrolide antibiotics; chemistry, biology, and practice. 2nd edn.. San Diego: Elsevier Science; 2002;p. 1–56
  9. Alvarez-Elcoro S, Yao JD. Antimicrobial macrolides in clinical practice. In:  Omura S editors. Macrolide antibiotics; chemistry, biology, and practice. 2nd edn.. San Diego: Elsevier Science; 2002;p. 363–402
  10. Sanazuka T, Omura S, Iwasaki S, Omura S. Chemical modification of macrolides. In:  Omura S editors. Macrolide antibiotics; chemistry, biology, and practice. 2nd edn.. San Diego: Elsevier Science; 2002;p. 99–180
  11. Gilbert DN, Moellering RC, Eliopoulos GM, MA S. The Sanford guide to antimicrobial therapy. Hyde Park: Antimicrobial Therapy, Inc.; 2004;p. 69
  12. Oritsu M. Effectiveness of macrolide antibiotics other than erythromycin (in Japanese). Therap Res. 1990;11:545–546
  13. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis. 1990;141:72–78
  14. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother. 1995;39:1688–1690
  15. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med. 2003;168:581–587
  16. Imamura Y, Yanagihara K, Mizuta Y, et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob Agents Chemother. 2004;48:3457–3461
  17. Shibuya Y, Wills PJ, Cole PJ. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respiration. 2001;68:615–619
  18. Yanagihara K, Tomono K, Imamura Y, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother. 2002;49:867–870
  19. Mitsuya Y, Kawai S, Kobayashi H. Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm. J Infect Chemother. 2000;6:45–50
  20. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest. 2004;125(2 Suppl):62S–69Squiz 69S
  21. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother. 2000;44:2869–2872
  22. Yamasaki T. [Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium–the effect of antimicrobial agents]. Kansenshogaku Zasshi. 1990;64:575–583
  23. Baumann U, Fischer JJ, Gudowius P, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection. 2001;29:7–11
  24. Tsang KW, Ng P, Ho PL, et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J. 2003;21:401–406
  25. Sofer D, Gilboa-Garber N, Belz A, Garber NC. ‘Subinhibitory’ erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Chemotherapy. 1999;45:335–341
  26. Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother. 2000;6:1–7
  27. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother. 1996;40:2271–2275
  28. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol. 2001;25:492–499
  29. Mitsuyama T, Tanaka T, Hidaka K, Abe M, Hara N. Inhibition by erythromycin of superoxide anion production by human polymorphonuclear leukocytes through the action of cyclic AMP-dependent protein kinase. Respiration. 1995;62:269–273
  30. Feldman C, Anderson R, Theron A, Mokgobu I, Cole PJ, Wilson R. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J. 1999;13:1022–1028
  31. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995;39:872–877
  32. Ogawa N, Sugawara Y, Fujiwara Y, Noma T. Roxithromycin promotes lymphocyte apoptosis in Dermatophagoides-sensitive asthma patients. Eur J Pharmacol. 2003;474:273–281
  33. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J. 1995;8:1451–1457
  34. Lin HC, Wang CH, Liu CY, Yu CT, Kuo HP. Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med. 2000;94:654–660
  35. Akamatsu H, Yamawaki M, Horio T. Effects of roxithromycin on adhesion molecules expressed on endothelial cells of the dermal microvasculature. J Int Med Res. 2001;29:523–527
  36. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration. 1996;63:42–48
  37. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med. 1997;156:266–271
  38. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA. Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother. 2001;45:401–406
  39. Suzaki H, Asano K, Ohki S, Kanai K, Mizutani T, Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm. 1999;8:199–204
  40. Shimane T, Asano K, Suzuki M, Hisamitsu T, Suzaki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Mediators Inflamm. 2001;10:323–332
  41. Schultz MJ, Speelman P, Hack CE, Buurman WA, van Deventer SJ, van Der Poll T. Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46:235–240
  42. Asano K, Kamakazu K, Hisamitsu T, Suzaki H. Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. Int Immunopharmacol. 2001;1:1913–1921
  43. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol. 1999;163:909–915
  44. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J. 1998;12:57–63
  45. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother. 1999;43:2678–2684
  46. Abe S, Nakamura H, Inoue S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2000;22:51–60
  47. Fumimori T, Honda S, Migita K, et al. Erythromycin suppresses the expression of cyclooxygenase-2 in rheumatoid synovial cells. J Rheumatol. 2004;31:436–441
  48. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol: accepted.
  49. Kita E, Sawaki M, Nishikawa F, et al. Enhanced interleukin production after long-term administration of erythromycin stearate. Pharmacology. 1990;41:177–183
  50. Konno S, Adachi M, Asano K, Kawazoe T, Okamoto K, Takahashi T. Influences of roxithromycin on cell-mediated immune responses. Life Sci. 1992;51:PL107–PL112
  51. Mitsuyama T, Hidaka K, Furuno T, Hara N. Release of nitric oxide and expression of constitutive nitric oxide synthase of human endothelial cells: enhancement by a 14-membered ring macrolide. Mol Cell Biochem. 1998;181:157–161
  52. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998;351:420
  53. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32:29–37
  54. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004;13:111–117
  55. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212–216
  56. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–642
  57. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. J Am Med Assoc. 2003;290:1749–1756
  58. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–1535
  59. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002;122:213–218
  60. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 1997;155:2018–2023
  61. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999;13:1371–1379
  62. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000;14:143–148
  63. Nagino K, Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect. 1997;3:432–439
  64. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829–1832
  65. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97:844–850
  66. Flotte TR, Loughlin GM. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol. 1991;10:178–182
  67. Beuther DA, Martin RJ. Antibiotics in asthma. Curr Allergy Asthma Rep. 2004;4:132–138
  68. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000;118:1826–1827
  69. Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J. 2004;23:714–717
  70. Lemanske RF. Is asthma an infectious disease?: Thomas A Neff lecture. Chest. 2003;123(3 Suppl):385S–390S
  71. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest. 2002;121:1782–1788
  72. Seear M, Hui H, Magee F, Bohn D, Cutz E. Bronchial casts in children: a proposed classification based on nine cases and a review of the literature. Am J Respir Crit Care Med. 1997;155:364–370
  73. Schultz KD, Oermann CM. Treatment of cast bronchitis with low-dose oral azithromycin. Pediatr Pulmonol. 2003;35:139–143
  74. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999–2000 study. J Antimicrob Chemother. 2002;50(Suppl S1):39–47
  75. Eitches RW, Rachelefsky GS, Katz RM, Mendoza GR, Siegel SC. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child. 1985;139:264–268
  76. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy. 1990;65:37–45
  77. Kamada AK, Hill MR, Ikle DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol. 1993;91:873–882
  78. Iino Y, Sasaki Y, Miyazawa T, Kodera K. Nasopharyngeal flora and drug susceptibility in children with macrolide therapy. Laryngoscope. 2003;113:1780–1785

PII: S1526-0542(05)00050-3

doi: 10.1016/j.prrv.2005.06.005

Paediatric Respiratory Reviews
Volume 6, Issue 3 , Pages 227-235 , September 2005

Article Tools

* Image Usage & Resolution